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The Association Between Antipsychotic Medication and Weight Gain
Brian Steen PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND 58202-9037

Abstract
² Antipsychotic medications are utilized for patients with many
mental health problems including schizophrenia, attention deficit
hyperactivity disorder, autism, bipolar mania, and psychotic
depression. The antipsychotic medications treat the symptoms
associated with these mental health disorders.
² Antipsychotic medications, while being efficacious to these
symptoms, can have unwanted side effects, including weight gain.
The purpose of this study was to determine if there is a strong
relationship with antipsychotic medication use and weight gain.
² The review of literature was conducted with an online search of
Cochrane, PubMed, and PsycInfo for journal articles, research
studies, and other scholarly reviews. Articles included in the
search described the proposed mechanisms of how antipsychotic
medications can result in weight gain.
² The literature review indicated antipsychotics contribute to
increased weight gain with second generation antipsychotic
medication use resulting in more weight gain than the use of first
generation antipsychotic medications.

Research Questions
² In treating patients with mental health disorders, is there an
association between the use of antipsychotic medications and weight
gain?
² In mental health patients prescribed antipsychotics, what are the
proposed mechanisms of antipsychotic induced weight gain?
² This scholarly project focused on the association between weight gain
and the use of antipsychotic medications. Additionally, the project
used research to investigate mechanisms by which antipsychotic
medication use can lead to weight gain.

Literature Review
² Arrango et al. (2009) conducted a clinical trial, which compared two
second generation antipsychotic medications, olanzapine and
quetiapine, for their side effects and efficacy over a 180-day period.
The olanzapine group gained more weight at 15.5 kg (p < 0.001),
than the quetiapine group at 5.4 kg (p = 0.004).

Introduction
² There are different types of antipsychotic medications including
first and second generation antipsychotics. The first generation
antipsychotics have been prescribed for mental health problems
since the 1950s. The second generation antipsychotics, also
known as atypical antipsychotics, are relatively newer
medications with their development in the 1980s
² According to the IMS Health Vector One National database, there
were over 6.8 million antipsychotic medications prescribed in the
United States in 2014.
² This increase of individuals accessing mental health treatment,
combined with the shortage of mental health professionals, means
that primary care providers will likely take on the responsibility
of managing a patient’s mental health medications.

Statement of the Problem
² In primary care, many patients will have mental health problems.
Primary care providers might not prescribe certain antipsychotics,
but they need to oversee the comprehensive health of the patients
on these medications, including the patients’ mental health.
However, due to a shortage of mental health professionals, many
primary health care providers also need to supervise the
antipsychotic medications.
² If antipsychotic medications cause weight gain, it can result in
non-compliance or increased risk of other comorbidities that
medical health professionals will need to manage as the primary
care providers.

² Martinez-Ortega et al. (2013) demonstrated that the second
generation antipsychotics were associated with more weight gain
then the first generation antipsychotics. One of the studies
analyzed showed a significantly higher (p < 0.05) mean weight
gain for olanzapine compared to risperidone and haloperidol.

Discussion

Applicability to Clinical
Practice
Increased Insulin
Resistance
Blocked D2 and M3
Receptors
Weight Gain

Antipsychotic
Medication Use

Blocked H1 Receptors

Increased Food Intake
and Weight Gain

² Scigliano and Ronchetti (2013) found that antipsychotic
medications were linked to an increase in insulin resistance. Insulin
resistance is a contributing factor to weight gain. The authors
proposed this mechanism works by increasing sympathetic tone
with the blocking of dopamine D2 receptors. Blocking the
muscarinic M3 receptors inhibits parasympathetic activity as well.
The combination of increased sympathetic tone and decreased
parasympathetic activity on the pancreatic islets can increase
insulin resistance
² Tek, Ratliff, Reutenauer, Ganguli, and O’malley (2014) described
on how antipsychotic induced weight gain is due to the blocking of
dopamine D2 receptors. These receptors are involved in the food
reward system. When the receptors are blocked, there can be an
increase in overeating, resulting in weight gain.
² Volpato, Zugno, and Quevedo (2013) proposed histamine H1
receptors regulate appetite. Antipsychotic medications block
histamine H1 receptors, leading to increased food consumption and
weight gain.

² The increase of individuals accessing mental health treatment,
combined with the shortage of mental health professionals, means
that primary care providers will likely take on the responsibility of
managing a patient’s mental health medications.
² Due to this increased prescribing responsibility, primary care
providers need to be aware of the antipsychotic medications and
the side effects to provide effective mental and physical health
plans. There is a strong likelihood of non-compliance and
discontinuation of antipsychotic medications due to the increase in
weight gain.
² Health care providers need to encourage a healthy diet and
exercise for their patients, especially those on antipsychotic
medications. Regular exercise could help reduce with weight gain
associated with the antipsychotic medication.
² The weight of each patient should be monitored and recorded
every visit. This weight monitoring can show results of how well
patients are adhering to their diet and exercise plans.
² Outside contributing factors such as lack of access to
transportation, inadequate healthy food choices, and financial
limitations can affect the patients’ ability to adhere to their
treatment plans. The cost of healthy food choices can result in
worse eating habits, adding to the weight gain side effects of
antipsychotic medications. Prescribing the appropriate generic
medications can help reduce the financial burden of patients.
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